Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 2/20 | 0.47 |
| ▸ | FYN | P06241 | 6/20 | 0.44 |
| ▸ | CCNC | P24863 | 1/20 | 0.42 |
| ▸ | CDK8 | P49336 | 1/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.40 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30845766 | 0.88 | CLK1 (0.46) | CHEK1FYNCCNCCDK8IRAK4 | |
| SCHEMBL30828852 | 0.88 | GRM2 (0.44) | CHEK1FYNCCNCCDK8IRAK4 | |
| SCHEMBL21014297 | 0.83 | KDM4E (0.50) | CHEK1FYNUSP30 | |
| SCHEMBL21033166 | 0.80 | USP30 (0.55) | CHEK1CCNCCDK8PTGS1PTGS2 | |
| SCHEMBL21033173 | 0.78 | DYRK1A (0.43) | PTGS1PTGS2 | |
| SCHEMBL10328709 | 0.77 | CHEK1 (0.50) | CHEK1FYNCCNCCDK8IRAK4 | |
| SCHEMBL21033307 | 0.76 | PTGS1 (0.41) | PTGS1PTGS2PIM1HRH4 | |
| SCHEMBL21033596 | 0.76 | PIK3CG (0.51) | CHEK1FYNCCNCCDK8IRAK4 | |
| SCHEMBL21033716 | 0.75 | CCNC (0.46) | CHEK1CCNCCDK8PIM1PIM2 | |
| SCHEMBL21033324 | 0.75 | PTGS1 (0.49) | PTGS1PTGS2HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371431-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT EPISCRIBE LLC | 2021-12-02 | — | — | US | disclosed |
| WO-2019102494-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2019-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371431-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | CHEK1 527/4885FYN 757/4885CCNC 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.